Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
Twitter
Google+
LinkedIn
Instagram
HOME
JOURNALS
ARTICLES IN PRESS
PSYCHOPHARMACOLOGY BULLETIN
FULL ISSUE STACKED PDFs
T.E.N.
MENTAL FITNESS
PSI
ONCOLOGY SPECTRUMS
PROJECTS
JOURNAL SUPPLEMENTS
PHYSICIAN ACADEMY SERIES
POCKET REFERENCE GUIDES
TEACHING MONOGRAPHS
MEDWORKS REPRINT SERIES
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOTROPIC PRESCRIBING INFORMATION
PSYCHOTROPIC DOSAGE RANGES
PSYCHOPHARMACOLOGY 101
PSYCHIATRIC RATING SCALES
NEWS
WE KNOW PSYCHIATRY
FEATURED ARTICLES
×
Home
/
Larry Alphs, MD, PhD: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
Larry Alphs, MD, PhD: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
$
30.00
Add to cart
Want a discount? Become a member by purchasing
Psychopharmacology Bulletin Subscription - Individual
!
Categories:
Psychopharmacology Bulletin
,
VOL 40 No. 2 Articles
Tags:
asenapine
,
clinical-trial
,
john-panagides
,
larry-alphs
,
md
,
ms
,
negative-symptoms
,
phd
,
schizophrenia
,
scott-lancaster
,
study-design
Description
Description
Larry Alphs, MD, PhD
ORIGINAL RESEARCH
Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS
Share On Facebook
Tweet This Product
Pin This Product
Mail This Product
Related products
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
$
0.00
Add to cart
Details
Signal Detection and Placebo Response in Schizophrenia: Parallels with Depression
$
30.00
Add to cart
Details
Calgary Depression Scale for Schizophrenia (CDSS)
$
0.00
Add to cart
Details
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety
$
30.00
Add to cart
Details
